Jacob McMillon
Family Medicine · Paragould, ARNPI 1467814137
Payments from drug & device makers
Across 280 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$358
- Amgen$349
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$341
- GSK$253
- Bayer$242
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,282100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 67 | $1,006 |
| AstraZeneca | 23 | $358 |
| Amgen | 26 | $349 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $341 |
| GSK | 17 | $253 |
| Bayer | 12 | $242 |
| Lilly USA, LLC | 16 | $237 |
| AbbVie | 12 | $196 |
| Johnson & Johnson | 13 | $179 |
| Pfizer | 16 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $153 |
| E.r. Squibb & Sons, L.L.C. | 9 | $134 |
| Boehringer Ingelheim | 6 | $97 |
| Genentech USA, Inc. | 5 | $73 |
| Idorsia Pharmaceuticals US Inc | 5 | $69 |
| Biohaven Pharmaceuticals, Inc. | 4 | $68 |
| Boston Scientific | 3 | $54 |
| Sumitomo Pharma America, Inc. | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Seqirus USA Inc | 1 | $30 |
| Novartis | 2 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Medtronic | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Merck | 1 | $11 |
How this compares
$4,302 in reported general payments places this provider in the 80th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $44,900 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $44,667 |
| MounjaroTirzepatide | 31 | $31,808 |
| JardianceEmpagliflozin | 34 | $30,898 |
| XareltoRivaroxaban | 35 | $24,390 |
| FarxigaDapagliflozin Propanediol | 29 | $23,757 |
| OzempicSemaglutide | 21 | $19,878 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $19,218 |
| GemtesaVibegron | 21 | $11,383 |
| LinzessLinaclotide | 17 | $11,006 |
| Pregabalin | 37 | $4,160 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,206 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $2,911 |
| Fentanyl | 14 | $2,817 |
| Pantoprazole Sodium | 202 | $2,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $177 | $44,90045 claims |
| GSKTrelegy Ellipta | $253 | $44,66738 claims |
| Lilly USA, LLCMounjaro | $237 | $31,80831 claims |
| Boehringer IngelheimJardiance | $97 | $30,89834 claims |
| Johnson & JohnsonXarelto | $179 | $24,39035 claims |
| AstraZenecaFarxiga | $358 | $23,75729 claims |
| Novo NordiskOzempic | $1,006 | $19,87821 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $11 | $19,21822 claims |
| AbbVieLinzess, Synthroid | $196 | $11,78729 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $51 | $11,38321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Paragould
- Hetal PatelParagould$147K
- Clarence KempParagould$16K
- Vincent LeeParagould$16K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.